The Insider Report

Coty Insiders Get Serious Again- How Long can it Remain Public?

by

It’s only going to get duller from here as we head into 3rd quarter earnings season blackout. With the trade war on hold until October and most insiders blacked out from buying pre-earnings release, there won’t be much to be learned from the insiders’ tea leaves. After the most buying all year, the market responded by rallying sharply. Now insiders have retreated with few exceptions.  They are Coty, the giant cosmetics company controlled by European investment firm JAB Ltd. Coty has struggled with weak sales and executive turnover. On July 19th, the company said it will restructure its operations and … Read more

Notable Insider Activity Week Ending 8-31-19

by

You have to love investors that put their money where their shareholders are. None are better than this than Richard Kinder, pipeline magnate. He bought almost $8 million of his namesake company, Kinder Morgan.  The 5% dividend yield looks both juicy and secure. Las Vegas Station Casino owner continues to pile into Red Rock Resorts. Maybe he hasn’t heard that a recession is on the way. Dish shareholders continue to bet the farm on the license spectrum and their highly risky and leveraged 5G buildout. 5G cellular is supposed to change everything and no doubt it will change Dish. Wayfair … Read more

Notable Insider Buys Week of 8-23-19 as Trump Tweets Scare Investors

by

We are throwing out AESE as this wasn’t filed correctly and upon further review, it was deemed not to be an open market purchase Fossil Group insiders bought $2.2 million worth of this watch and teen wear company. FOSL group is in a race down the down staircase with decreasing revenues and decreasing SGA. Change Health Care is McKesson’s giant conglomerate of health tech companies recently gone public with Blackstone as their private equity investors. I haven’t had good luck with private equity IPOs, saddled with debt and selling institutional investors. This one doesn’t have any long term debt but it … Read more

Insiders Put the Petal to the Metal as Animal Spirits Show Signs of Life

by

Animal spirits are picking up.  This is the most buying we’ve seen since the market sell-off last December. One thing for sure, Insiders buy stocks when they think they are cheap.  Highlights are: Several insiders bought GE stock immediately prior to and immediately after Harry Markapolis’s interview on CNBC where he alleged fraud. Axogen Chairman bought $1 million worth of stock after the company she leads plunged 30% on weaker earnings forecast Outdoor billboard leader, Clear Channel newly appointed Chairman bought $913k at $2.28 per share.  CCO is loaded with debt. Three CIT insiders took advantage of low prices to … Read more

‘s Getting Interesting- Insider Buying Picks Up Week Ending 8-9-19

by

After weeks of dull action, insider buying has finally picked up. Part of it is the end of 2nd Quarter earnings blackout and part of it is the market sell-off.  The highlights: Charlie Egren, the founder of Dish, is making a massive bet on 5G, buying assets in the pending TMobile Sprint network and committing billions to buy more bandwidth.  Its a bet the farm expensive gamble on a player late to the game.  But if the competing networks are slow in getting 5G rolled out, Dish might be able to lumber in and get a piece of the future … Read more

Stock Market gets Clobbered – 4 Insiders buy over $6 million of Pharma Giant AbbVie $ABBV

by

Another dull week for insider buying but not the market. Markets have the worst week of the year.  This hardly comes as a surprise as insiders are an endangered species, the lowest ratio of buying on record according to the Washington Service.  A word to the hopeful, there is always something to buy but expect it to be painful.   The pharmaceutical giant has seen its price plummet since announcing the purchase of Allergan. Abbivies’s #1 drug, Humira, is coming off patent.  Humira is the brand name of the biologic medicine adalimumab and was first approved for the treatment of rheumatoid arthritis … Read more

Trump needs the Farmers more specifically the Farm States in 2020 Buy Archer Daniel Midland $ADM

by

It’s no secret Trump loves the farmers. It’s also no secret his trade war with China is killing them too. That’s why we are buying Archer Daniels Midland.  Bioethanol, corn and the feedstocks for it are big business for the farm industry.  Trump is stalling on extending refinery biofuel credits this year in a reversal of his palsy-walsy reversal of his 2016  election payback to Carl Icahn. Rember Icahn was his big and early financial street cred backer in the run-up to the election.  Icahn also lobbied hard to have them reduced so his refinery CVR Energy could get out … Read more

Insider Buying is Anemic- BUT WE STILL FIND SOMETHING TO BUY $APD,$CCI,$URI

by

Insider Buying is Anemic- Insider Buying is Anemic- BUT WE STILL FIND SOMETHING TO BUY $APD,$CCI,$URI -try these names on for size Week Ending 7-26-19 Two large-cap buyers have excellent track records. Air Products and Chemicals (APD) CEO Ghasemi is batting 8 out of 9 on winning trades showing exemplary timing.  It’s also very bullish when the CEO buys the stock at the top of the price range as was his $4.54 M buy at $227.16 Another interesting buy was Chairman Martin Landis purchase of cell phone tower REIT Crown Castle International (CCI) $2,07 M at $127.33.  It’s hard to … Read more

Eyenovia merits a closer look $EVEN

by

CEO Ianchulev purchase of microcap Eyenovia merits a closer look. This was part of a spot 4.38 M share spot secondary at $2.78. Eyenovia is marketing a high tech eyedropper.  The 100-year-old eyedropper could be disrupted by Eyenovia. Buyer beware though, it’s easy to get in but not so easy to get out of this low volume late-stage money-losing biotech. Health Equity insiders score big by scooping up 10,000 shares each on secondary. Unfortunately, there was no way to act on this until the 15th SEC filing after the stock had risen 10 points. Insiders are required to file within … Read more

‘s Insider Buys

by

Odonate ODT’s Chairman and CEO Kevin Tang has made open market purchases of more than $36 million in so far this June, including $10 million on the spot secondary at the highest price his paid all year.   This is a bet the farm investment but seems to be validated by the market as ODT stock has more than tripled this year. Three insiders buy AbbVie after Wall Street choked on their purchase of Allergan.  Do two out of favor big pharma companies add up to 4? Wall Street certainly doesn’t think so. Carnival Cruise CEO Donald Arnold bought just under … Read more

We took money off the table today in a bad tape with a good trade on Biogen

by

Biogen spiked handsomely today and we took money off the table in a bad tape. We wrote on May 4th, that we were particularly excited about Biogen. Two insiders had bought material amounts of stock Biogen when the stock lost more than a quarter of its value during premarket trading Thursday morning after the company announced it would discontinue trials of its Alzheimer’s disease drug.   CEO Vounatsos increased his holdings by 21.6% purchasing 4,351 shares at $231.48.  Longtime board member and biotech guru hedge fund manager, Alexander Denner laid down a cool $27.2 million increasing his holdings by 22.1%. Anxiety … Read more

‘s Refinery Blows Up- Better to be Lucky than Good

by

Insider Buying Week Ending June 21, 2019 PBF Energy CEO Buys $950,000 in Stock Moments before Competitor’s Refinery Blows Up reminding me of the saying when it comes to Wall Street, Sometimes It’s Better to be Lucky than Good Ron Perleman thinks Scientific Games is his lottery ticket. Investors aren’t so lucky. Prospect Capital Corp insiders like its 10% plus yield yet the stock is lower now than a year ago in spite of the bull run in yield sensitive names. Medicine Man Technologies is no cure for poverty.  Insiders can play games too. Insiders sell stock for many reasons, … Read more

Occidental Petroleum Insiders Say Enough is Enough- Our Stock is too Cheap to Ignore

by

Insider Buying Week Ending June 14, 2019 Occidental Petroleum insiders say enough is enough, quit trashing our stock by collectively buying over $4 million worth in the open market. Oil stocks are big underperformers but ever since Oxy announced the purchase of Anadarko, the stock has been in free fall. American Asset Trust insiders buying at new highs and continue to get rewarded at this diversified REIT. REMAX founder and once barred insider Linder returns with a vengeance scooping up another $2.9 million adding to his buys from last week. Guess CEO increases his holdings by over 230% buying nearly … Read more

Insiders See Opportunity in All Kinds of Markets, Especially Bad Ones

by

Insider Buying Week Ending June 7, 2019 American Airline insiders buy stock in beaten down airline lifting price action. Waiting on large payback from Boeing 737 Max grounding.  American is incredibly cheap will have significant free cash flow.and will be a direct beneficiary of increased trade with Mexico as it flies more routes than any other airline. John Idol, Chairman of the Board and CEO of Capri Holdings goes all in fashion conglomerate holding company with luxury iconic brands, Versace, Jimmy Choo, and Michael Koors. RE/MAX Holdings disclosed that its co-founder and chairman David Liniger bought a total of 122.9K … Read more

Stock Market gets Clobbered- Insiders are Nibbling

by

Insider Buying Week Ending May 31, 2019
Jay Hoag of Zillow Goes All In

Trump rocks market with trade wars on multiple fronts.  Impromptu tweet on Friday about tariffs on Mexico linked to immigration enforcement cap off a month that most investors would like to forget.  Monday’s action is likely not to be any better for FANGS with the news that the Justice Department is opening up an anti-trust investigation on Google aka Alphabet.   S&P 500 Wipes Out $4 Trillion in Its Second-Worst May Since the ‘60s.  Insiders are nibbling at a few names but in the short term are losing money like everyone else.

U.S. Stocks Have Now Fallen For 5 Weeks In A Row but Some Insiders are Buying

by

The market gets scarier by the day.  Wealthy individuals pulled their money out at record rates not seen in seven years. Black swans seem to be showing up in multiple corners of the world, China trade war, Iran real war, just to mention a few. None the less that didn’t stop a few insiders with conviction loading up on their company’s stock. In fact, it’s the most buying we have seen in some time. We highlight those over $200,000 in this report.

Notable Insider Buys Week Ending May 17, 2019

by

The market gets scarier by the day.  Wealthy individuals pulled their money out at record rates not seen in seven years. Black swans seem to be showing up in multiple corners of the world, China trade war, Iran real war, just to mention a few. None the less that didn’t stop a few insiders with conviction loading up on their company’s stock. In fact, it’s the most buying we have seen in some time. We highlight those over $200,000 in this report.

Notable Insider Buys Week Ending May 10, 2019

by

The market suffered its worse loss of the year, but that didn’t stop some insiders buying their own stock. We highlight those over $200,000 in this report. In this report, we highlight open market purchases from employees and directors of more than $200,000.  Insiders sell stock for many reasons, but they generally buy for just one – to make money.  As a standard, we only look at material amounts of money, $200 thousand or more, as anything less could just be window dressing. The bar is different from selling because the natural state of management is to be sellers. This … Read more

No Time For Heroes

by

  The Insiders Fund, went 80% to cash last Wednesday in part market-driven, in part disillusioned with the likelihood of a China trade deal.  The Fund had a great run up this year, over 24%, and now many stocks appear grossly over-valued.  The “cloud” software stocks seem to have nothing but clouds themselves supporting their valuations.  To top it off Uber went public at an $85 billion dollar valuation. This is for a company that has never made money, maybe never will as the drivers are estimated to be making less than minimum wage after factoring the cost of their … Read more

Notable Insider Buys and Sells Week Ending May 3, 2019 or Sell in May, Go Away

by

  Several new buys this week signaled a return to animal spirits for a small group.  The majority of corporate America beat the drum beat, sell in May, Go Away. The market marched to a new high but not every stock participated. These buys represent value in an overvalued market, perhaps one long in the tooth.  We don’t aim to predict tops or bottoms but when insiders buy large amounts of their own company’s stock, they do it for one reason; to make money. We are highlighting notable buys over $200,000 as this represents something more than window dressing. Buys … Read more

Biogen is a Table Thumping Buy $BIIB

by

            Several new buys this week signaled a return to animal spirits. We are particularly excited about Biogen. Biogen (BIIB) had a double whammy over the last two weeks. Two insiders bought material amounts of stock Biogen when the stock lost more than a quarter of its value during premarket trading Thursday morning after the company announced it would discontinue trials of its Alzheimer’s disease drug.   CEO Vounatsos increased his holdings by 21.6% purchasing 4,351 shares at $231.48.  Longtime board member and biotech guru hedge fund manager, Alexander Denner laid down a cool $27.2 million … Read more

Notable Insider Buys and Sales Week Ending 4-19-19

by

It was a dull week for insider trading, duller even than the miserly week before.  Last week would make you think it was a crime to buy your own company’s stock.   Of course, we are in the throes of the 1st quarter earnings blackout, but insiders still find ways to unload their holdings though. There were a couple of noteworthy buys.

Buys

JPM JPMorgan Chase & Co (Mkt Cap: $338.9B) – Director Mellody Hobson Mellody steps up buying JPM after the stock bounced 5% on 1st quarter earnings surprise, spending $2.2M to purchase 19,700 at $111.30. This increased her holdings by 31.2%.  That might have meant something but six insiders also sold $28.1 million worth.

LAWS Lawson Products (Mkt Cap: $274.0M) Chairman of the Board, John King must have liked what he saw as he bought $1.2M worth of stock after the Company reported a healthy leap in earnings. Lawson Products(LAWS), a product supplier to the maintenance, repair, and operations market, reported Q1 adjusted earnings of $0.48 per share, up from $0.25 in the same period a year ago and topping the estimate of $0.29 from analysts polled by Capital IQ.

Total revenue of $91.3 million was up from $84.4 million in the same period ending in March a year ago and topped the Street projection of $89.8 million.

Sales
BBY Best Buy  Perhaps things aren’t as sunny as we think at Best Buy. Two insiders sold $19.9 million worth of stock in outright sales, including Chairman Joly’s sale of 171,711 shares at $73.68.

Not much of interest here either. Insiders continue to unload stock using the Rule 10b5-1 loophole that allows insiders to sell stock right through any imposed earnings blackout period. It’s hard to read anything much into these sales other than the fact, that I would rather see insiders buying than selling their stock. The timing of these transactions shed little light on short term price movements, though.

In this report, we examined open market purchases from employees and directors.  Insiders sell stock for many reasons, but they generally buy for just one – to make money.  As a standard, we only look at material amounts of money, $200 thousand or more, as anything less could just be window dressing. The bar is different from selling because the natural state of management is to be sellers. This is because most companies provide significant amounts of management compensation packages as stock. Therefore, with selling, we analyze for unusual patterns, such as insiders selling 25 percent or more of their holdings or multiple insiders selling near 52-week lows. Another red flag is large planned sale programs that start without warning. We generally ignore 10 percent shareholders as they tend to be OPM (other people’s money) and not the SMART money we are trying to go to school on.  Although this info is available for free from the SEC’s Web site, Edgar, we subscribe to the Washington Service as they provide a way to manage and make sense of the vast realms of data.

To learn more about our strategy, visit our website here. We welcome your comments on our analysis. We may own positions, long or short, in any of these names and are under no obligation to disclose that. If you would like to hear more about how you can get involved with the Insiders Fund, please schedule some time on my calendar

 

Notable Insider Buys and Sales Week Ending 4-12-19

by

It was a dull week for insider trading, duller even than the dull week before.  Last week would make you think it was a crime to buy your own company’s stock.   Of course, we are in the throes of the 1st quarter earnings blackout, but insiders still find ways to unload their holdings though.

Buys

ABEO Abeo Therapeutics Two directors bought stock in this biotech.  One was a first time purchase for a sizeable amount. We normally don’t think much of new directors buys as this is pretty much a riskless transaction as they will get paid in compensation as much as they might be expected to buy.  Director Buono bought 70,000 shares at $7.80 per share and that’s worth noticing.
Abeona Therapeutics announced that the FDA has granted fast track designation to ABO-101, the company’s novel one-time gene therapy for Sanfilippo syndrome type B, or MPS IIIB. ABO-101 is designed to deliver a functional copy of the NAGLU gene to the central nervous system and peripheral tissues. Abeona is enrolling eligible patients with MPS IIIB at sites in the U.S. and Spain and expects to activate additional sites globally this year to accelerate enrollment.
But the story gets thicker and particularly thornier;
wrote in January 2017 that ABEO Director Mark Ahn appears to have settled an SEC investigation for his involvement in an illegal stock promotion when he served as the CEO of Galena Pharmaceuticals (GALE).

Before being sued, Ahn allegedly promoted GALE with illegal stock promotion campaigns costing hundreds of thousands of dollars, then dumped millions of dollars of his stock, enriching himself.

This is not surprising to us as ABEO’s board is filled with stock promoters, including Chairman Steven Rouhandeh, who has a long and similar history of promotion and self-enrichment.

Two sell-side “analysts” defending ABEO were involved in numerous China fraud wipeouts while at Rodman & Renshaw.

It doesn’t appear that this director is working there any longer and to the company’s credit, new director Buono comes with good credentials but most importantly he is buying $546,000 dollars worth of good credit. Among Mr. Buono’s many accomplishments was bringing AAA public in November 2015, on the NASDAQ exchange. The company traded under the ticker symbol AAAP, until it was acquired by Novartis in January 2018.

LNDC Landec Director Obus doubled down on his currently losing hand by purchasing 60,000 shares at $10.33.  Landec does a lot of things as taken from its 10k: Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets. It operates through two segments, Packaged Fresh Vegetables and Biomaterials.  Revenue and Debt have risen while profits have shrunk, not a pretty picture.
TCDA Tricinda Director Parker bought 20,000 shares at $36. Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
SYRS Pharmaceuticals Director Srinivas increased his holdings by 50% purchasing 533,332 shares at $7.50 spending $4 million dollars in an underwritten offering. Piper Jaffray was one of the underwriters and their analyst Edward Tenthoff lowered his price target for Syros Pharmaceuticals to $24 from $28 to account for dilution of the company’s recent $70M capital raise. The analyst, however, reiterates an Overweight rating on the name. Syros is developing potentially best-in-class CDK7 inhibitors, Tenthoff tells investors in a research note. He points out that data from the expansion cohorts in ovarian cancer are expected in Q4.
Sales

Not much of interest here either. Insiders continue to unload stock using the Rule 10b5-1 loophole that allows insiders to sell stock right through any imposed earnings blackout period. It’s hard to read anything much into these sales other than the fact, that I would rather see insiders buying than selling their stock. The timing of these transactions shed little light on short term price movements, though.

In this report, we examined open market purchases from employees and directors.  Insiders sell stock for many reasons, but they generally buy for just one – to make money.  As a standard, we only look at material amounts of money, $200 thousand or more, as anything less could just be window dressing. The bar is different from selling because the natural state of management is to be sellers. This is because most companies provide significant amounts of management compensation packages as stock. Therefore, with selling, we analyze for unusual patterns, such as insiders selling 25 percent or more of their holdings or multiple insiders selling near 52-week lows. Another red flag is large planned sale programs that start without warning. We generally ignore 10 percent shareholders as they tend to be OPM (other people’s money) and not the SMART money we are trying to go to school on.  Although this info is available for free from the SEC’s Web site, Edgar, we subscribe to the Washington Service as they provide a way to manage and make sense of the vast realms of data.

To learn more about our strategy, visit our website here. We welcome your comments on our analysis. We may own positions, long or short, in any of these names and are under no obligation to disclose that. If you would like to hear more about how you can get involved with the Insiders Fund, please schedule some time on my calendar

 

Notable Insider Buys and Sales Week Ending 4-6-19

by

It was a dull week on insider buying, the week before.  Last week would make you think it was a crime to buy your own company’s stock.   Of course, we are in the throes of the 1st quarter earnings blackout, but insiders still find ways to unload their holdings though.

Buys

WBA Walgreens Boots Alliance-Walgreens Boots Alliance Q2 ‘was a very disappointing quarter for us’ according to management’s earnings conference call.  The stock was pummeled with numerous analyst downgrades.  The stock got cheap enough for the COO, to pull the trigger and bought $1 million worth of WBA at $54.58.  We are taking this lay-up but can’t stay we will stay here for long.

Rev Revlon Chairman of the Board, Perlman continues to pour money into the cosmetics giant. He purchased two lots, one for $2.34 million at $20.22, the other one of $1.4 million at $21.10.

COST Costco Wholesale A director bought 3000 shares near a 52 week high at $242.85.  It’s hard to put a lot of conviction into this purchase even though it was a sizeable amount, $727k. Buying market darlings at 52 week highs is not your typical MO for an insider.

RMBL Rumble On Dir Dixon bought 50,415 at $4.77 of this motorcycle marketplace.  We are doing more research on this name but it looks interesting. We are trying to figure out where Ebay Marketplace and Carvana’s success could transfer to this name.

Sales

Not much of interest here either. Insiders continue to unload stock using the Rule 10b5-1 loophole that allows insiders to sell stock right through any imposed earnings blackout period. It’s hard to read anything much into these sales other than the fact, that I would rather see insiders buying than selling their stock. The timing of these transactions shed little light on short term price movements, though.

In this report, we examined open market purchases from employees and directors.  Insiders sell stock for many reasons, but they generally buy for just one – to make money.  As a standard, we only look at material amounts of money, $200 thousand or more, as anything less could just be window dressing. The bar is different from selling because the natural state of management is to be sellers. This is because most companies provide significant amounts of management compensation packages as stock. Therefore, with selling, we analyze for unusual patterns, such as insiders selling 25 percent or more of their holdings or multiple insiders selling near 52-week lows. Another red flag is large planned sale programs that start without warning. We generally ignore 10 percent shareholders as they tend to be OPM (other people’s money) and not the SMART money we are trying to go to school on.  Although this info is available for free from the SEC’s Web site, Edgar, we subscribe to the Washington Service as they provide a way to manage and make sense of the vast realms of data.

To learn more about our strategy, visit our website here. We welcome your comments on our analysis. We may own positions, long or short, in any of these names and are under no obligation to disclose that.

Notable Insider Buys and Sales Week Ending 3-29-19

by

Talk about a dull week on insider buying.  This is all that stuck out. Of course we are in the throes of the 1st quarter earnings blackout, but still, this is very thin. Insiders still find ways to unload their holdings though.

Buys

ETRN Equitrans Midstream Corp– three insiders bought $446.K of this midstream natural gas company. On February 21, 2018, EQT Corporation (EQT) announced plans to separate its separately managed gathering, transmission and storage, and water services operations (Midstream Business) from its natural gas, oil and natural gas liquids development, production and sales and commercial operations (Upstream Business). The separation of the Midstream Business from the Upstream Business will culminate in the spinoff from EQT of a new company named Equitrans Midstream Corporation. Equitrans Midstream will trade on the NYSE under the ticker symbol ETRN.

CLR Continental Resources Harold Hamm CEO bought $34 million at $42.95.  Hamm has been a consistent buyer of stock in the last 5 years and has yet to make any headway in these purchases. We see no reason why this latest buy would be any different.
Sales

Insiders always find ways to sell with  “planned sales” which in reality is just a legal loophole around the SEC restrictions on insider selling during earnings blackout periods.  Some of the more notable ones are described below.

ULTA Ulta Beauty Inc. Insiders dumped a bunch of ULTA the week ending 3/22/19 and last week was no different. Five insiders took advantage of lifetime high prices to unload $199.8  million worth of this beauty chain. As of November 3, 2018, the company operated 1,163 retail stores across 50 states.

We think they have the right idea and would be sellers ourselves. Ulta has had stellar growth but its slowing.

CRM Salesforce Eight insiders sold $19.1 million worth of stock through a combination of sales and option exercises.  Salesforce is a bloated overpriced cloud-based CRM.  It invented the field so there are a lot of entrenched, hard to switch users but now there are many cheaper, viable competitors. Eventually, the market will perceive the moat is draining and the emperor has no clothes. This is a short but beware the market can remain irrational longer than you can be solvent.

SMAR Smartsheet Inc Five insiders sold a combination of stock and options worth $8.7 million. Smartsheet Inc. provides cloud-based platform for execution of work. It enables teams and organizations to plan, capture, manage, automate, and report on work. The company offers Smartdashboards that provides the status of work to align individuals, managers, and executive

 

In this report, we examined open market purchases from employees and directors.  Insiders sell stock for many reasons, but they generally buy for just one – to make money.  As a standard, we only look at material amounts of money, $200 thousand or more, as anything less could just be window dressing. The bar is different from selling because the natural state of management is to be sellers. This is because most companies provide significant amounts of management compensation packages as stock. Therefore, with selling, we analyze for unusual patterns, such as insiders selling 25 percent or more of their holdings or multiple insiders selling near 52-week lows. Another red flag is large planned sale programs that start without warning. We generally ignore 10 percent shareholders as they tend to be OPM (other people’s money) and not the SMART money we are trying to go to school on.  Although this info is available for free from the SEC’s Web site, Edgar, we subscribe to the Washington Service as they provide a way to manage and make sense of the vast realms of data.

To learn more about our strategy, visit our website here. We welcome your comments on our analysis. We may own positions, long or short, in any of these names and are under no obligation to disclose that.

Notable Insider Buys and Sales Week Ending 1-4-19 No One is Buying Yet!

by

  I wrote in last week’s blog post, that “The next month will tell everything.  Every meaningful rout in the market has ended when a crescendo of insider buying has restored confidence and validated values.  We are not there yet but the question is will we get there when the 4th quarter blackout period ends.  Right now we are in a period where most insiders are prohibited from buying stock so close to the quarter end. This graph below shows a significant tick up in insider buying, the highest its been in a year but considering how grim the news … Read more

Notable Insider Buys and Sales Week Ending 12-21-18

by

The next month will tell everything.  Every meaningful rout in the market has ended when a crescendo of insider buying has restored confidence and validated values.  We are not there yet but the question is will we get there when the 4th quarter blackout period ends.  Right now we are in a period where most insiders are prohibited from buying stock so close to the quarter end. This graph below shows a significant tick up in insider buying, the highest its been in a year but considering how grim the news is, I’d like to see a crescendo of buying … Read more

Notable Insider Buys and Sales Week Ending 12-14-18

by

As the market has sold off, insiders are starting to take advantage of lower prices. This last week was disappointing as there were few notable buys.  They are listed below: Buys NMRK Newmark Group- CEO Barry Gosin purchased $9 million worth at an average price of $9.05 per share. Newmark Group, Inc. provides commercial real estate services in the United States and internationally. Its investor/owner services and products include capital markets, such as investment sales; and agency leasing, property management, valuation and advisory, and diligence and underwriting, as well as government sponsored enterprise lending, loan servicing, debt and structured finance, and … Read more

Panic around the corner? Notable Insider Buys and Sales Week Ending 12-7-18

by

As the market has sold off, insiders are starting to take advantage of lower prices. We are not yet at a level  where insiders are full throated buyers but several are willing to bet sizable sums of money. Panic is around the corner but not here yet. We outline the most notable ones below. Buys MHK Mowhak Industries  Billionaire Filip Balcaen continues to bet on global carpet manufacturer Mohawk Industries.  It’s nice to have the luxury of waiting out market anxieties. UAL United Airlines Dir Edward Shapiro is batting 1000 when he purchased 30,000 at $92.57.  I personally think Southwest is … Read more

Notable Insider Buys and Sales Week Ending 11-23-18

by

As the market has sold off, insiders are starting to take advantage of lower prices. Take note of this graph supplied by the Washington Service. Buys ET Energy Transfer LP  Pipeline behemoth ET recently ended their two class share structure of general partner and limited partners consolidating the company into one entity, ET. Insiders have been steady buyers.  Last week Chairman of the Board Kelcy bought 3 million shares at an average price of $15.34.  ET and other pipeline companies have had a rough week as the price of crude oil collapsed due to fears of supply glut and global … Read more